研究单位：[1]BeiGene[2]Tongji Hospital of Tongji Medical College Wuhan, Hubei, China, 430030[3]Jiangsu Province Hospital Nanjing, Jiangsu, China, 215006[4]The affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China, 221000[5]The first Bethune Hospital of Jilin University Changchun, Jilin, China, 130021[6]Xia Hua Hospital Affiliated to Shanghai Jiao Tong University School of medicine Shanghai, Shanghai, China, 200092[7]West China Hospital, Sichuan University Chengdu, Sichuan, China, 610041[8]Institute of Hematology and Hospital of Blood Disease Tianjin, Tianjin, China, 3100020[9]Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin, China[10]Zhejiang Cancer Hospital Hangzhou, Zhejiang, China, 310022[11]The First Affiliated Hospital of Zhejiang University Hangzhou, Zhejiang, China, 31003[12]Fudan University Shanghai Cancer Center Shanghai, China, 200025[13]Fakultni nemocnice Hradec Kralove Hradec Králové, Czechia[14]Fakultni nemocnice Ostrava Ostrava, Czechia, 70852[15]Institut Bergonie Bordeaux, France, 33076[16]Hôpital Saint-Louis Paris, France, 75010[17]Fujian Medical University Union Hospital Fuzhou, Fujian, China, 350001[18]Guangdong Province People's Hospital Guangzhou, Guandong, China, 510062[19]Nanfang hospital of Southern Medical University Guangzhou, Guandong, China, 510515[20]Affiliated Tumor Hospital of Harbin Medical University Harbin, Heilongjiang, China, 150000[21]Affiliated Tumor Hospital of Harbin Medical University Harbin, Heilongjiang, China, 150000[22]St. Vincent's Hospital Melbourne Fitzroy, Australia, 3065[23]Geelong University Hospital Geelong, Australia
The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.
